MDMB-BINACA

In today's world, MDMB-BINACA has become a topic of great relevance and interest to a large number of individuals and sectors. Since its emergence, MDMB-BINACA has generated debates and controversies in different areas, and its impact continues to be the subject of study and analysis. In this article, we will delve into the fascinating world of MDMB-BINACA, exploring its dimensions, implications and possible future developments. Through a detailed and rigorous analysis, we aim to shed light on this exciting and significant topic, offering the reader a deep and enriching vision of MDMB-BINACA.

MDMB-BINACA
Identifiers
  • methyl (2S)-2--3,3-dimethylbutanoate
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC19H27N3O3
Molar mass345.443 g·mol−1
3D model (JSmol)
  • CCCCN1C2=CC=CC=C2C(=N1)C(=O)N(C(=O)OC)C(C)(C)C
  • InChI=1S/C19H27N3O3/c1-6-7-12-22-14-11-9-8-10-13(14)15(21-22)17(23)20-16(18(24)25-5)19(2,3)4/h8-11,16H,6-7,12H2,1-5H3,(H,20,23)/t16-/m1/s1
  • Key:YHAWFWPNIXPRDT-MRXNPFEDSA-N

MDMB-BINACA (MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. It has a similar chemical structure to potent cannabinoid agonists previously reported such as ADB-BUTINACA and MDMB-5'Br-BUTINACA, and is believed to have similar effects.[1]

See also

References

  1. ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.


Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.